Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06410248 · ClinicalTrials.gov registry record · Phase 1

Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma

A Phase 1 study of Recurrent Glioblastoma, IDH-Wildtype and Recurrent WHO Grade 4 Glioma, sponsored by Northwestern University.

Active
Registry status
Phase 1
Development phase
30
Enrollment target
1
Study location

NCT06410248: Active Phase 1 study of Recurrent Glioblastoma, IDH-Wildtype and Recurrent WHO Grade 4 Glioma, sponsored by Northwestern University.

NCT06410248 is a Phase 1 study of Recurrent Glioblastoma, IDH-Wildtype and Recurrent WHO Grade 4 Glioma that is active but no longer recruiting, run by Northwestern University. The registered enrollment target is 30 participants, below the 38-participant average among 4 other Recurrent Glioblastoma, IDH-Wildtype trials with a reported enrollment target (21% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06410248, a Phase 1 study of Recurrent Glioblastoma, IDH-Wildtype and Recurrent WHO Grade 4 Glioma, is active but no longer recruiting, sponsored by Northwestern University.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

This phase I trial tests the safety, side effects, and best dose of triapine in combination with temozolomide in treating patients with glioblastoma that has come back after a period of improvement (recurrent). Triapine inhibits an enzyme responsible for producing molecules required for the production of deoxyribonucleic acid (DNA), which may inhibit tumor cell growth. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill tumor cells and slow down or stop tumor growth. Giving triapine in combination with temozolomide may be safe, tolerable, and/or effective in treating patients with recurrent glioblastoma.

Primary Outcome

The recommended phase 2 dose will be based on treatment-emergent and drug-related toxicity. Dose limiting toxicities and adverse events (AEs) will be assessed by Common Terminology Criteria for Adverse Events (CTCAE) version (v.) 5.0.

Conditions Studied

Recurrent Glioblastoma, IDH-Wildtype Recurrent WHO Grade 4 Glioma Recurrent WHO Grade 2 Glioma Recurrent WHO Grade 3 Glioma

Interventions

  • PROCEDURE Biospecimen Collection
  • PROCEDURE Magnetic Resonance Imaging
  • OTHER Questionnaire Administration
  • DRUG Temozolomide
  • PROCEDURE Resection

Study Locations (1)

Illinois

  • Northwestern University - Chicago

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2024-07-23
Est. Completion 2030-05-12
Phase Phase 1
Northwestern University

1,209 total trials

What the registry record for NCT06410248 still lists

NCT06410248 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 38-participant average among 4 other Recurrent Glioblastoma, IDH-Wildtype trials with a reported enrollment target (21% lower).

The record links to 4 conditions, with Recurrent Glioblastoma, IDH-Wildtype appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT06410248 reports a single indexed study location in Illinois.

Frequently Asked Questions

What is clinical trial NCT06410248 about?

NCT06410248 is a clinical study titled "Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma". This phase I trial tests the safety, side effects, and best dose of triapine in combination with temozolomide in treating patients with glioblastoma that has come back after a period of improvement (recurrent). Triapine inhibits an enzyme responsible for producing molecules required for the producti...

What is the current status of trial NCT06410248?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2024-07-23. Estimated completion is 2030-05-12.

What conditions does trial NCT06410248 study?

This clinical trial studies the following conditions: Recurrent Glioblastoma, IDH-Wildtype, Recurrent WHO Grade 4 Glioma, Recurrent WHO Grade 2 Glioma, Recurrent WHO Grade 3 Glioma.

What interventions are being tested in trial NCT06410248?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Questionnaire Administration (OTHER), Temozolomide (DRUG), Resection (PROCEDURE).

Who is sponsoring clinical trial NCT06410248?

This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06410248 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Recurrent Glioblastoma, IDH-Wildtype

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT06410248, the US trial registry maintained by the National Library of Medicine. NCT06410248 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.